BioPharma Resources

Drug Trial Radar · NCT00822614

Safety of Fentanyl TAIFUN Treatment

The Safety of Fentanyl TAIFUN Treatment After Titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients

Last checked: Nov 19, 2026Latest source record: Jan 14, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

500

Planned (sponsor's estimate)

Start

Dec 2008

Primary completion

Dec 2009

Study completion Jan 2010

Sponsor

Lead sponsor
Akela Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jan 14, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate hte Safety of Fentanyl TAIFUN Treatment after titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy

Conditions

  • Breakthrough Cancer Pain

Interventions

  • Fentanyl TAIFUNDrug

    Inhalation of Fentanyl via TAIFUN inhaler

  • OpioidDrug

    Current optimized BTP treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AE ProfileTime frame: 28 Days
  2. To characterize the safety of Fentanyl TAIFUN treatment vs. the current BTP treatment based on the AE profileTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NZOZ

    Włocławek, Wolnosc, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.